DuoGenic StemCells (ROCO:7607) Cyclically Adjusted PS Ratio: (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7607 DuoGenic StemCells Corp ROCO:7607
24 GF Score
Price NT$12.85
GF Value NT$51.45
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is DuoGenic StemCells Cyclically Adjusted PS Ratio?

DuoGenic StemCells does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

DuoGenic StemCells  (ROCO:7607) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

DuoGenic StemCells Cyclically Adjusted PS Ratio Related Terms

DuoGenic StemCells Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for DuoGenic StemCells's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells Cyclically Adjusted PS Ratio Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
0.00 0.00 0.00 0.00 0.00

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

ROCO:7607 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, DuoGenic StemCells's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Cyclically Adjusted PS Ratio falls into.


ROCO:7607
24GF Score
DuoGenic StemCells Corp ROCO:7607
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DuoGenic StemCells Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

DuoGenic StemCells does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?

Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued. The current stock price of NT$12.85 is trading 75% below its estimated GF Value™ of NT$51.45. GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.

Key valuation signals for ROCO:7607:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$51.45 vs. price of NT$12.85 (75% below fair value)
  • GF Score™: 24/100 with 2 warning signs

No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DuoGenic StemCells Business Description

Address Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
24GF Score

Get the complete analysis for ROCO:7607

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.85
Price
NT$51.45
GF Value